Efficacy and Safety of Nab-Paclitaxel Chemotherapy for Patients with Gastric Carcinoma: A Systematic Review and Single Arm Meta-analysis-Reference-Cited by-同舟云学术

Efficacy and Safety of Nab-Paclitaxel Chemotherapy for Patients with Gastric Carcinoma: A Systematic Review and Single Arm Meta-analysis

Published:2023-04-20 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Madeeh Alyaa Khaled¹,Farouk Hossam Khaled¹,Belal Mohamed Mohamed²,Ramadan Sara²,Al-Masri Batool Emad³,Samier Mohamed⁴,Gadallah Salama Ahmed⁴,Khapoli Naseba⁵,Nashwan Abdulqadir J.⁶,AbdelQadir Yossef Hassan²

Affiliation:

1. Fayoum University

2. Alexandria University

3. The University of Jordan

4. Al-Azher University

5. University of Zawia

6. Hamad Medical Corporation

Abstract

Abstract Aim This study aims to investigate the efficacy of nab-paclitaxel mono-chemotherapy as a second-line treatment for previously treated adenocarcinoma patients.Methods We conducted a systematic review and meta-analysis of prospective single-arm clinical studies that tested nab-paclitaxel monotherapy for treating gastric carcinoma. The review was conducted in accordance with PRISMA.Results We included 6 studies with a total of 271 patients. The pooled analysis of response rate, overall survival, and progression-free survival were 0.21 (95% CI: [0.16,0.28]), 11.65 (95% CI: [10.56, 12.75]), and 2.983 (95% CI: [2.625, 3.342]), respectively. There was no statistically significant difference between the doses regarding response rate and progression-free survival. However, the overall survival of the 150 mg/m2 dose was statistically significantly higher than the 260 mg/m2 dose. The treatment was associated with manageable toxicity profiles.Conclusion Nab-paclitaxel mono-chemotherapy is an effective treatment option for previously treated and recurrent gastric cancer with a manageable toxicity profile. Future studies should aim to compare Nab-paclitaxel to other agents in direct head-to head comparison.

Publisher

Research Square Platform LLC

Reference22 articles.

1. Globocan. 2018 Latest global cancer data – IARC [Internet]. [cited 2023 Jan 26]. Available from: https://www.iarc.who.int/infographics/globocan-2018-latest-global-cancer-data/.

2. Cancer today [Internet]. [cited 2023 Feb 9]. Available from: http://gco.iarc.fr/today/home.

3. Nivolumab in patients with. advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed [Internet]. [cited 2023 Jan 26]. Available from: https://pubmed.ncbi.nlm.nih.gov/28993052/.

4. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial;Mavroudis D;Am J Clin Oncol

5. Clinical benefit with. docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group - PubMed [Internet]. [cited 2023 Jan 26]. Available from: https://pubmed.ncbi.nlm.nih.gov/17664467/.